Fig. 5.

(A) Bar charts for the significantly affected metabolites involved in LPS biosynthesis and its aminoarabinose modification following polymyxin B (PMB), tamoxifen (TAM), and combination (COM) treatment at 15 min *(≥ 1.0-log₂-fold, p ≤ .05; FDR ≤ 0.05); (≥ 0.59-log₂-fold, p ≤ .05; FDR ≤ 0.05). Control samples (blue), PMB (purple), TAM (green), and COM (red). (B) Bar charts and a diagram for the significantly impacted intermediates of LPS formation and its aminoarabinose modification after polymyxin B (PMB), tamoxifen (TAM), and the combination treatment at 1 h (≥ 1.0-log₂-fold, p ≤ .05; FDR ≤ 0.05).